Back to results
US 2026/0308267 A1Published application
Anti-ox40 antibody and uses thereof
AssigneeHutchison Medipharma Limited
InventorsYizhen YANG, Yu CAI, Xiong LI, Lei ZHOU, Weiguo QING, Wei-Guo SU
Life of this patent
Estimating the term…
Abstract
Provided are an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method thereof and the use for treating OX40-related diseases or conditions.
Claims13
-30. (canceled)
An isolated nucleic acid, encoding an isolated anti-OX40 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:
- (1) one to three selected from HCDR1, HCDR2 and HCDR3 of a heavy chain variable region (VH), wherein the amino acid sequence of the VH is as set forth in SEQ ID NO:
- 1, 2, 3, 4 or 5;
- and/or
- (2) one to three selected from LCDR1, LCDR2 and LCDR3 of a light chain variable region (VL), wherein the amino acid sequence of the VL is as set forth in SEQ ID NO:
- 6, 7, 8, 9 or 10;
- preferably, wherein the antibody or antigen-binding fragment thereof comprises a heavy variable region (VH) comprising the three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region (VH) of SEQ ID NO:
- 2 and a light variable region (VL) comprising the three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of the variable chain light region (VL) of SEQ ID NO:
- 7,
- wherein, the antibody or antigen-binding fragment thereof does not comprise an Fc region variant which is human IgG1 N297A, and wherein the amino acid residues in the Fc region are numbered in accordance with the EU numbering system.
6 more elements
Dependencies are inferred from the claim text.